List of investigational post-traumatic stress disorder drugs

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by editing the page to add missing items, with references to reliable sources.

This is a list of investigational post-traumatic stress disorder (PTSD) drugs, or drugs that are currently under development for clinical use for the treatment of post-traumatic stress disorder (PTSD) but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]".

This list was last comprehensively updated in September 2025. It is likely to become outdated with time.

Under development

Preregistration

• Brexpiprazole (Lu-AF41156; OPC-34712; Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator)
• Midomafetamine (MDMA; Ecstasy) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT₂ receptor agonist, and entactogen

Phase 3

• Aripiprazole (Abilify; OPC-14597) – atypical antipsychotic (non-selective monoamine receptor modulator)
• Cyclobenzaprine (KRL-102; TNX-102; Tonmya) – tricyclic antidepressant (monoamine reuptake inhibitor and monoamine receptor modulator)

Phase 2

• 7-Oxoprasterone (7-keto-DHEA; HBL-9001; HL-9001; At-Ease) – undefined mechanism of action (immunomodulator)
• Amdiglurax (ALTO-100; NSI-189) – unknown mechanism of action (hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator)
• BI-1358894 – transient receptor potential cation channel TRPC4 and TRPC5 inhibitor
• Cannabidiol (A-1002-N5S; CBD; Nantheia™) – cannabinoid, various actions
• CORT-108297 (ADS-108297) – glucocorticoid receptor antagonist
• Dronabinol (BX-1) – cannabinoid CB₁ and CB₂ receptor agonist
• Iloperidone (Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril) – atypical antipsychotic (non-selective monoamine receptor modulator)
• Ketamine intranasal (Ereska; PMI-100; PMI-150; SLS-002; TUR-002) – NMDA receptor antagonist and dissociative hallucinogen
• Lithium cocrystal (AL-001; LiProSal; lithium salicylate/L-proline cocrystal) – undefined mechanism of action
• Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and psychedelic hallucinogen
• Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and psychedelic hallucinogen
• Soclenicant (BNC-210; IW-2143) – α₇-nicotinic acetylcholine receptor antagonist
• SRX-246 (API-246) – vasopressin V_1A receptor antagonist
• Xenon (NBTX-001) – NMDA receptor antagonist

Phase 1/2

• PT-00114 – corticotropin-releasing hormone (CRH) inhibitor

Phase 1

• Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α₂-adrenergic receptor agonist
• (R)-Midomafetamine ((R)-MDMA; EMP-01) – serotonin–norepinephrine releasing agent, weak serotonin 5-HT₂ receptor agonist, and entactogen
• Mirodenafil (AR-1001) – phosphodiesterase PDE5 inhibitor

Preclinical

• ART-2612 (ART2612) – FABP5 inhibitor
• BMB-202 – serotonin 5-HT_2A receptor agonist
• Cycloserine/lurasidone (NRX-101) – combination of cycloserine (NMDA receptor partial agonist) and lurasidone (atypical antipsychotic or non-selective monoamine receptor modulator)
• Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (H₁ receptor antagonist, muscarinic acetylcholine receptor antagonist, serotonin receptor antagonist, other actions) and prazosin (α₁-adrenergic receptor antagonist)
• ENX-205 – dopamine D₂ and D₃ receptor antagonist and serotonin 5-HT_1A and 5-HT_2A receptor agonist
• Leu-enkephalin (leucine enkephalin; Envelta; METDoloron; NES-100; NM-0127; NM-127; PES200) – δ-opioid receptor agonist
• Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor, antiglucocorticoid) and oxazepam (GABA_A receptor positive allosteric modulator, benzodiazepine)
• NB-127 – undefined mechanism of action
• NNI-351 – DYRK kinase inhibitor, nerve growth factor (NGF) stimulant
• Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent
• Research programme: neurotransmitter modulators - Awakn Life Sciences (AWKN-SDN-14) – serotonin–norepinephrine–dopamine reuptake inhibitors

Not under development

Development suspended

• Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK₃ receptor antagonist

No development reported

• Bupropion (amfebutamone; Wellbutrin) – norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator
• Elcubragistat (ABX-1431; Lu-AG06466) – monoacylglycerol lipase (MAGL) inhibitor
• EX-597 (KDS-4103; ORG-231295; URB-597) – fatty acid amide hydrolase (FAAH) inhibitor
• IMM-201 (DAR-901; SRL-172; heat-killed Mycobacterium vaccae strain NCTC-11659) – immunomodulator, immunostimulant, and vaccine
• Ketamine sublingual (SLS-003; Wafermine) – NMDA receptor antagonist and dissociative hallucinogen
• Lanicemine (ARL-15896; ARR-15896; BHV-5500; FPL-15896) – NMDA receptor antagonist
• Research programme: allosteric modulators - Addex Therapeutics – various actions
• Research programme: cannabis extract therapeutics - Cannabis Science
• Research programme: cannabinoid-based therapeutics - Axim Biotechnologies (Cannabidiol/Gabapentin; Cannbleph™)
• Research programme: CNS disorders therapeutics - Sage Therapeutics (SAGE 105; SGE-202; SGE-301; SGE-516) – GABA_A receptor modulators and NMDA receptor modulators
• Topiramate (Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topimax; Topina) – various actions

Discontinued

• Acamprosate controlled-release (SNC-102) – various actions
• ALTO-202 – NMDA receptor antagonist
• Balovaptan (RG-7314; RO-5028442; RO-5285119) – vasopressin V₁ receptor antagonist
• Carvedilol (Coreg) – α₁-, β₁-, and β₂-adrenergic receptor antagonist and dual alpha/beta blocker
• Crinecerfont (Crenessity; NBI-74788; SSR-125543) – corticotropin releasing factor receptor 1 (CRF₁R) antagonist
• ENX-105 – dopamine D₂ and D₃ receptor agonist, dopamine D₄ receptor agonist, and serotonin 5-HT_1A and 5-HT_2A receptor agonist
• Fluoxetine (Prozac, Sarafem) – selective serotonin reuptake inhibitor
• Ganaxolone (GNX; CCD-1042; Ztalmy) – GABA_A receptor positive allosteric modulator and neurosteroid
• JZP-150 (PF-04457845; PF-4457845; PF-’845) – fatty acid amide hydrolase (FAAH) inhibitor
• Nabiximols (tetrahydrocannabinol/cannabidiol; THC/CBD; GW-1000; JZP-378; Nabidiolex®/Tetranabinex®; Sativex) – cannabinoid receptor modulator, other actions
• Naloxone/tianeptine (TNX-601) – combination of tianeptine (weak and atypical μ-opioid receptor agonist) and naloxone (orally inactive opioid receptor antagonist)
• Nepicastat (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor
• NYX-783 – NMDA receptor modulator
• Orvepitant (GW-823296, GW823296X) – neurokinin NK₁ receptor antagonist
• Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu₂ and mGlu₃ receptor agonist
• PRAX-114 – GABA modulator
• PRX-3140 (PRX-03140; NTC-942) – serotonin 5-HT₄ receptor agonist
• Verucerfont (GSK-561679; NBI-77860) – corticotropin releasing factor receptor 1 (CRF₁R) antagonist

Clinically used drugs

Approved drugs

Selective serotonin reuptake inhibitors (SSRIs)

• Paroxetine (Dropax, Paxil, Seroxat, Serestill) – selective serotonin reuptake inhibitor (SSRI)
• Sertraline (Lustral, Zoloft) – selective serotonin reuptake inhibitor (SSRI)

Off-label drugs

• Antipsychotics (non-selective monoamine receptor modulators) (e.g., olanzapine, quetiapine, risperidone)
• Benzodiazepines (GABA_A receptor positive allosteric modulators) (e.g., alprazolam, clonazepam, diazepam, lorazepam)
• Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, sotalol)
• Cannabinoids (cannabinoid receptor agonists) (e.g., cannabis, THC, nabilone)
• NMDA receptor antagonists (dissociative hallucinogens) (e.g., ketamine, esketamine)
• Other selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram, escitalopram, fluoxetine, fluvoxamine)
• Prazosin (α₁-adrenergic receptor antagonist)
• Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., desvenlafaxine, duloxetine, milnacipran, venlafaxine)
• Topiramate (various actions)
• Tricyclic antidepressants (TCAs) (e.g., imipramine, amitriptyline)

See also

• List of investigational drugs
• List of investigational anxiolytics
• Anxiolytic

External links

• AdisInsight - Springer